In 2011, mutations were identified in five genes (BRAF, CSMD3, SLC5A1, CNTN6 and OR8J) by means of whole-exome high-throughput sequencing performed on the (>90 %) CD19+ tumour cells from a patient with HCL and on the (>98 %) CD19− mononuclear cells from the same patient at the time of remission [6]. Here, CD19 is linked to neoplasm.